New Clinical Responses for AGEN1181 Presented at AACR
April 10 2021 - 8:35AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today presented new clinical data on AGEN1181, its
next-generation anti-CTLA-4 antibody, at the American Association
for Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021.
“The preclinical and translational data in
conjunction with our updated clinical data with AGEN1181 alone or
in combination with our PD-1, balstilimab, continue to strongly
support and differentiate our next-generation CTLA-4 antibody,”
said Steven O’Day, MD, Chief Medical Officer of Agenus. “AGEN1181
is showing activity in patients with tumors which typically do not
respond to first-generation CTLA-4 and PD-1 antibodies. Equally
important, the safety data continues to show no immune mediated
hypophysitis, pneumonitis, or hepatitis to date. Given the efficacy
and favorable safety profile, we have expanded AGEN1181 into Phase
2 in colorectal cancer patients as a first step in our efforts to
expand to additional important cancer indications.”
In two separate presentations at AACR, Agenus
showcased the optimal performance of AGEN1181 in relevant models.
In addition, as the clinical data matures, additional responses as
well as a conversion from a partial response to a complete
response, have been observed. The new data announced today include
the following clinical responses:
- New partial
response in the first melanoma patient treated
(monotherapy)
- New conversion to complete
response in ovarian cancer patient (AGEN1181 plus
balstilimab)
- Partial response
in microsatellite stable (MSS) colorectal cancer patient (AGEN1181
plus balstilimab)
- Partial response
in PD-L1(-) ovarian cancer patient (AGEN1181 plus balstilimab)
- Partial response
in MSS colorectal cancer patient (AGEN1181 plus balstilimab)
- Complete response
in PD-L1(-) MSS endometrial cancer patient (monotherapy)
- Complete response by
PET in PD-L1(-) MSS endometrial cancer patient (AGEN1181
plus balstilimab)
Presentation Details:E-poster
presentations were made available on the conference platform on
April 10 at 8:30am ET. Posters with accompanying audio will be
available for viewing to meeting registrants until June 21.
Session: PO.IM02.10 -
Therapeutic Antibodies, Including Engineered
AntibodiesPoster title: Fc-enhanced anti-CTLA-4
antibody, AGEN1181: New mechanistic insights for potent antitumor
immunity and combination potential in treatment-resistant solid
tumorsAbstract number: 1878Presenting
author: Antoine Tanne, PhD
Session: PO.IM02.05 - Immune
Monitoring / Clinical CorrelatesPoster title:
Characterization of the pharmacodynamic activity of AGEN1181, an
Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1
antibody balstilimabAbstract number:
1677Presenting author: Irina Shapiro, PhD
In addition, Dr. Steven O’Day, Chief Medical
Officer, Dr. Dhan Chand, Scientific Director, Head of Drug
Discovery, and Dr. Jennifer Buell, President and COO, at Agenus,
will participate in a webcast hosted by Dr. Matt Phipps of William
Blair on Saturday, April 10, 2021 at 10:30 a.m. ET.
Registration for the webinar can be done in advance
at https://williamblair.zoom.us/webinar/register/WN_4tTw7GEFQPC2qC4B3TzrfQ.
A replay will be available after the call on the
Events & Presentations page of the Agenus website at
https://investor.agenusbio.com/events-and-presentations.
About AgenusAgenus is a
clinical-stage immuno-oncology company focused on the discovery and
development of therapies that engage the body's immune system to
fight cancer. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more information, please visit
www.agenusbio.com and our Twitter handle @agenus_bio. Information
that may be important to investors will be routinely posted on our
website and Twitter.
Forward-Looking StatementsThis
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities
laws, including statements regarding the therapeutic potential of
AGEN1181 alone and in combination with other agents, as well as the
potential to use such therapies in additional cancer indications.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly
HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024